1. Academic Validation
  2. Ingenol esters induce apoptosis in Jurkat cells through an AP-1 and NF-kappaB independent pathway

Ingenol esters induce apoptosis in Jurkat cells through an AP-1 and NF-kappaB independent pathway

  • Chem Biol. 2001 Aug;8(8):767-78. doi: 10.1016/s1074-5521(01)00048-5.
M Blanco-Molina 1 G C Tron A Macho C Lucena M A Calzado E Muñoz G Appendino
Affiliations

Affiliation

  • 1 Departamento de Biología Celular, Fisiología e Immunología, Universidad de Córdoba, Spain. [email protected]
Abstract

Background: Ingenol derivatives have received constant and multidisciplinary attention on account of their pleiotropic pattern of biological activity. This includes activation of protein kinase C (PKC), tumour-promotion, Anticancer, and anti-HIV properties, and the possibility of dissecting co-cancerogenic and clinically useful activities has been demonstrated. Certain ingenol esters show powerful Anticancer activity, and a structure-activity relationship model to discriminate between their apoptotic and non-apoptotic properties has been developed.

Results: The polyhydroxylated southern region of ingenol was selectively modified, using the Anticancer and PKC Activator ingenol 3,20-dibenzoate (IDB) as a lead compound. The evaluation of IDB analogues in Apoptosis assays showed strict structure-activity relationships, benzoylation of the 20-hydroxyl being required to trigger Apoptosis through a pathway involving Caspase-3 and occurring at the specific cell cycle checkpoint that controls the S-M phase transition. Conversely, a study on the activation of the PKC-dependent transcription factors AP-1 and NF-kappaB by IDB analogues showed significant molecular flexibility, including tolerance to changes at the 3- and 20-hydroxyls. IDB-induced Apoptosis was independent of activation of PKC, since it was not affected by treatment with the non-isoform-selective PKC Inhibitor GF 109230X0.

Conclusions: Remarkable deviations from the tumour-promotion pharmacophore were observed for both the apoptotic and the PKC-activating properties of IDB analogues, showing that ingenol is a viable template to selectively target crucial pathways involved in tumour promotion and development. Since the apoptotic and the PKC-activating properties of ingenoids are mediated by different pathways and governed by distinct structure-activity relationships, it is possible to dissect them by suitable chemical modification. In this context, the esterification pattern of the 5- and 20-hydroxyls is critical.

Figures
Products